Senti Biosciences (SNTI) said Wednesday that the US Food and Drug Administration has granted orphan drug designation for SENTI-202, a drug candidate for relapsed or refractory acute myeloid leukemia.
The experimental drug is a first, off-the-shelf cancer immunotherapy natural killer cell treatment designed to target acute myeloid leukemia and other hematologic malignancies, the company said.
Senti-202 is currently being evaluated in a phase 1 clinical trial to assess its safety and efficacy, Senti Biosciences said.
The orphan drug designation provides benefits such as tax credits, exemptions from certain FDA fees, and potential market exclusivity for seven years, the company added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。